Related Experiment Videos
Gene therapy for thioguanine-resistant human leukemia
Molecular Biology & Medicine
|June 1, 1987
Summary
Retroviral gene therapy can overcome drug resistance in leukemia cells. Transferring the HGPRT gene sensitized resistant cells to 6-thioguanine, demonstrating feasibility for gene transfer.
Area of Science:
- Molecular Biology
- Cancer Genetics
- Gene Therapy
Background:
- Acquired resistance to chemotherapy is a major challenge in treating human promyelocytic leukemia.
- Gene therapy offers a potential strategy to re-sensitize resistant cancer cells to cytotoxic drugs.
Purpose of the Study:
- To assess the feasibility of using retroviral gene therapy to overcome drug resistance in leukemia.
- To determine the efficiency of sensitizing hypoxanthine-guanine phosphoribosyltransferase (HGPRT)-deficient leukemia cells to 6-thioguanine using a retrovirus carrying the human HGPRT gene.
Main Methods:
- Retroviral transduction of HGPRT-negative human promyelocytic leukemia cells with a vector encoding the human HGPRT gene.
- Assessment of cell sensitization to 6-thioguanine by measuring clonogenic survival.
- Analysis of proviral integration, HGPRT expression, and mutation rates in sensitized cells.
Main Results:
- A single three-hour retroviral exposure sensitized 70% of clonogenic cells to 6-thioguanine.
- Sensitization efficacy depended on virus concentration and exposure duration.
- Successfully transduced cells expressed HGPRT, with varying mutation rates in the inserted gene.
Conclusions:
- Retroviral gene transfer of the HGPRT gene is a feasible approach to overcome 6-thioguanine resistance in human leukemia cells.
- This strategy demonstrates the potential for gene therapy in overcoming drug resistance in hematological malignancies.